CN1927391A - Collagen eye drops - Google Patents
Collagen eye drops Download PDFInfo
- Publication number
- CN1927391A CN1927391A CN 200510098424 CN200510098424A CN1927391A CN 1927391 A CN1927391 A CN 1927391A CN 200510098424 CN200510098424 CN 200510098424 CN 200510098424 A CN200510098424 A CN 200510098424A CN 1927391 A CN1927391 A CN 1927391A
- Authority
- CN
- China
- Prior art keywords
- collagen
- eye drops
- eyes
- eye
- examples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a kind of collagen protein gutta, which is the mixture of collagen protein and iso-osmia solution. For every 100ml collagen protein gutta, there is 10-500mg collage protein, which is extracted from the mouth tails; the rest is the iso-osmia, which is 5% amylaceum solution. The gutta has a good osmosis effect as well as a long effective time; besides, it can keep the eyeball moist, relieve the asthenopia, enforce the nutrient of ocular region and promote the agglutination.
Description
Technical field
The present invention relates to Medicines.
Background technology
With the collagen protein is that the application of eye drop aspect collyrium that raw material is made yet there are no.Eye drop of the prior art, what be used for treatments such as xerophthalmia mostly is synthetic, its biocompatibility is not ideal enough.For further improving curative effect, be necessary to develop new eye drop.
Summary of the invention
The purpose of this invention is to provide a kind of collagen eye drops, have that osmotic effect is good, property of medicine effective time is long, make eyeball keep moistening, alleviating asthenopia, the nutrition of increase eye and promote effect such as wound healing with certain viscosity.
The object of the present invention is achieved like this:
A kind of collagen eye drops, its key component are collagen protein, and its component and component ratio are: in every 100ml collagen eye drops, collagen protein is 10-500mg, and all the other are isotonic solution;
Described collagen protein extracts from Mus tail or pig, tendon Bovis seu Bubali tendon.
Described isotonic solution is 5% glucose solution.
The present invention has following actively useful effect:
This product is to be the collagen eye drops that raw material is made with the collagen protein, is certain viscosity, and its component is an active collagen liquid.This product has effects such as the eyeball of making maintenance is moistening, alleviating asthenopia, promotion wound healing, in its component, add an amount of isotonic solution, this product can be used for: cornea mechanical damage, corneal ulcer, punctate keratitis, the slight chemical injury of cornea, cornea hot injury's treatment; Prevent xerophthalmia and alleviate asthenopia etc.Its special efficacy is to keep the viscosity of collagen protein to be difficult for being diluted by tear when user mode, thereby eye is had the effective time of good penetration medical effect and prolongation medicinal liquid, thereby gives full play to collagen protein nutrition and the effect that promotes the cell growth.
The specific embodiment
Embodiment one: the component of described collagen eye drops and component ratio are: in every 100ml collagen eye drops, collagen protein is 150mg, and all the other are isotonic solution, and this isotonic solution is 5% glucose solution.
This routine collagen eye drops is through following test:
Through the application of 10 wheat harvesting periods, the patient of collagen eye drops treatment keratopathy is totally 14 examples (23 eyes).Eyes 9 examples (18 eyes) wherein, simple eye 5 examples (5 eyes); Male's 8 examples (14 eyes), women's 6 examples (9 eyes), 12 years old to 70 years old age.Operation on cornea 3 examples (5 eyes) wherein, corneal injury 3 examples (5 eyes), punctate keratitis 3 examples (5 eyes), corneal ulcer 2 examples (3 eyes), xerophthalmia 1 example (2 eyes), hot injury's 1 example (1 eye), eye chemical injury (slightly) 1 example (2 eyes).
The average curative day of therapeutic effect corneal injury 1.4 days, punctate keratitis 6.3 days, corneal ulcer 5.5 days, chemical injury (slightly) 4.4 days, the result shows that the therapeutic effect of this routine collagen eye drops is good, healing time is fast, and is without any side effects.
Embodiment two: the component of described collagen eye drops and component ratio are: in every 100ml collagen eye drops, collagen protein is 100mg, and all the other are isotonic solution, and this isotonic solution is 5% glucose solution.
This routine collagen eye drops is through following test:
Through the application of 10 wheat harvesting periods, the patient of collagen eye drops treatment keratopathy is totally 14 examples (23 eyes).Wherein, eyes 9 examples (18 eyes), simple eye 5 examples (5 eyes); Male's 8 examples (14 eyes), women's 6 examples (9 eyes), 12 years old to 70 years old age.Operation on cornea 3 examples (5 eyes) wherein, corneal injury 3 examples (5 eyes), punctate keratitis 3 examples (5 eyes), corneal ulcer 2 examples (3 eyes), xerophthalmia 1 example (2 eyes), hot injury's 1 example (1 eye), eye chemical injury (slightly) 1 example (2 eyes).
The average curative day of therapeutic effect corneal injury 1.5 days, punctate keratitis 6.4 days, corneal ulcer 5.6 days, chemical injury (slightly) 4.5 days, the result shows that the therapeutic effect of this routine collagen eye drops is good, healing time is fast, and is without any side effects.
Embodiment three: the component of described collagen eye drops and component ratio are: in every 100ml collagen eye drops, collagen protein is 50mg, and all the other are isotonic solution, and this isotonic solution is 5% glucose solution.
This routine collagen eye drops is through following test:
Through the application of 10 wheat harvesting periods, the patient of collagen eye drops treatment keratopathy is totally 14 examples (23 eyes), eyes 9 examples (18 eyes), simple eye 5 examples (5 eyes); Male's 8 examples (16 eyes), women's 6 examples (9 eyes), 12 years old to 70 years old age.Operation on cornea 3 examples (5 eyes) wherein, corneal injury 3 examples (5 eyes), punctate keratitis 3 examples (5 eyes), corneal ulcer 2 examples (3 eyes), xerophthalmia 1 example (2 eyes), hot injury's 1 example (2 eyes), eye chemical injury (slightly) 1 example (1 eye).
The average curative day of therapeutic effect corneal injury 1.5 days, punctate keratitis 6.5 days, corneal ulcer 5.65 days, chemical injury (slightly) 4.55 days, the result shows that the therapeutic effect of this routine collagen eye drops is good, healing time is fast, and is without any side effects.
In sum, among the 42 routine patients of application, the average curative day of therapeutic effect corneal injury 1.5 days, punctate keratitis 6.4 days, corneal ulcer 5.6 days, chemical injury (slightly) 4.5 days, the result shows that the therapeutic effect of protocollagen eye drop is good, and healing time is fast, and is without any side effects.
The method for preparing above-mentioned collagen eye drops, this method comprises following concrete steps:
(1) be raw material with cleaning level SD rat Mus musculus caudalis key, preparation procedure: the execution rat → getting rat afterbody → clean → sterilization → aseptic condition separates the musculus caudalis tendon down;
(2) distilled water flushing tendon → acetic acid or hydrochloric acid acid molten → pepsin or papain enzymolysis → saltout → water dialysis → collagen liquid.
(3) in collagen liquid, add the isotonic solution mix homogeneously, make collagen eye drops;
(4) the collagen eye drops fill is entered eye-drop liquid bottle, reinstall in the packing of strict sterilization, filling and sealing under aseptic condition is made bottled collagen eye drops.
The characteristics of collagen eye drops of the present invention:
Active collagen is a kind of bioactive biomacromolecule material that possesses, it is the Main Ingredients and Appearance of extracellular matrix, the hypertrophy of pair cell, differentiation, motion and joint lubrication, wound healing, the electrolytical distribution of moisture, blood coagulation, and lubricated, the index of refraction of eyeball etc. has important facilitation, the effect that the growth of pair cell has inducing and conducts.Possess lubricating function: the unsymmetry of tropocollagen molecule structure and a large amount of hydrophilic groups because of existence, make it to have the adhesiveness and the hydrophilic of height, when cell migration, can play a part to support and lubricate, so collagen eye drops has excellent lubricating function and health care, for xerophthalmia and asthenopic quality; Treat evident in efficacy.Trophism: the necessary nutrient of eye that can contain collagen protein, make active reinforcement of collagen protein of eye, the integrity that keeps horny layer moisture and fibre structure improves eye cells survival environment and the metabolism that promotes eye, reaches the purpose of nutrition.
The procollagen eye drop is difficult for diluted when splashing into eye, can keep long drug effect.
Dress collagen eye drops bottle is that medical material is made, and the content that is contained in collagen protein and the mixture of isotonic solution in the eye-drop liquid bottle is identical.
Described collagen liquid is: contain collagen protein 2.01～8.01mg in the 1ml collagen liquid, all the other are aqueous solution.
This product using method: adult every day 4-6 time, 1-2 drips at every turn.The dosage that the child uses is identical with adult's dosage.
Claims (5)
1. collagen eye drops, its key component is the mixture of collagen protein and isotonic solution, it is characterized in that: its component and component ratio are: in every 100ml collagen eye drops, collagen protein is 10-500mg, and all the other are isotonic solution;
Described collagen protein extracts from Mus tail or pig, tendon Bovis seu Bubali tendon.
2. collagen eye drops as claimed in claim 1 is characterized in that: described component and component ratio are: in every 100ml collagen eye drops, collagen protein is 150mg, and all the other are isotonic solution.
3. collagen eye drops as claimed in claim 1 is characterized in that: described component and component ratio are: in every 100ml collagen eye drops, collagen protein is 100mg, and all the other are isotonic solution.
4. collagen eye drops as claimed in claim 1 is characterized in that: described component and component ratio are: in every 100ml collagen eye drops, collagen protein is 50mg, and all the other are isotonic solution.
5. as claim 1 or 2 or 3 or 4 described collagen eye drops, it is characterized in that: described isotonic solution is 5% glucose solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510098424 CN1927391A (en) | 2005-09-08 | 2005-09-08 | Collagen eye drops |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510098424 CN1927391A (en) | 2005-09-08 | 2005-09-08 | Collagen eye drops |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1927391A true CN1927391A (en) | 2007-03-14 |
Family
ID=37857622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510098424 Pending CN1927391A (en) | 2005-09-08 | 2005-09-08 | Collagen eye drops |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1927391A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102210856A (en) * | 2011-06-02 | 2011-10-12 | 陕西巨子生物技术有限公司 | Collagen eye drops and preparation method thereof |
| CN102671184A (en) * | 2011-03-09 | 2012-09-19 | 广州加原医药科技有限公司 | Application of marine fish polypeptide in preparing eye drops for relieving asthenopia |
| CN105617350A (en) * | 2016-02-03 | 2016-06-01 | 王媛 | Extraction method of sheep sclera collagen, ophthalmic gel and preparation method thereof |
| CN105999235A (en) * | 2016-07-19 | 2016-10-12 | 上海建华精细生物制品有限公司 | Extracellular matrix imitated eye drops and preparation method thereof |
-
2005
- 2005-09-08 CN CN 200510098424 patent/CN1927391A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102671184A (en) * | 2011-03-09 | 2012-09-19 | 广州加原医药科技有限公司 | Application of marine fish polypeptide in preparing eye drops for relieving asthenopia |
| CN102210856A (en) * | 2011-06-02 | 2011-10-12 | 陕西巨子生物技术有限公司 | Collagen eye drops and preparation method thereof |
| CN102210856B (en) * | 2011-06-02 | 2012-10-03 | 陕西巨子生物技术有限公司 | Collagen eye drops and preparation method thereof |
| CN105617350A (en) * | 2016-02-03 | 2016-06-01 | 王媛 | Extraction method of sheep sclera collagen, ophthalmic gel and preparation method thereof |
| CN105999235A (en) * | 2016-07-19 | 2016-10-12 | 上海建华精细生物制品有限公司 | Extracellular matrix imitated eye drops and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huynh et al. | Hyaluronic acid applications in ophthalmology, rheumatology, and dermatology | |
| US10383796B2 (en) | Application and uses of PRG4 and therapeutic modulation thereof | |
| CA2588044C (en) | Ophthalmic compositions and methods for treating eyes | |
| CN100381169C (en) | Composite collagen eye drops | |
| US8974803B2 (en) | Injectable biomaterials | |
| CN103860625A (en) | Cranberry extract eye ophthalmic preparation and preparation method and uses thereof | |
| CN1927391A (en) | Collagen eye drops | |
| CN1927393A (en) | Composite collagen gel | |
| CN111803441A (en) | Sodium hyaluronate eye drops containing 0.01% atropine and preparation method thereof | |
| CN102188695B (en) | Ophthalmic gel composition | |
| CN102178936B (en) | Methods for preparing collagen oleostock and moistening eyedrops | |
| CN102579492A (en) | Sodium hyaluronate eyedrop containing deproteinized calf blood extractive and preparation method thereof | |
| CN105214071A (en) | A kind of size variance eye drop and preparation method thereof | |
| CN112891326B (en) | Natamycin-loaded alginic acid gel medicine film and preparation method thereof | |
| US20230146680A1 (en) | Method for producing enhanced anti-inflammatory / anti-catabolic agents from autologous physiological fluid | |
| CN107802597B (en) | Sodium hyaluronate composition and preparation method and application thereof | |
| US20150290248A1 (en) | Fibrous component for health, performance, and aesthetic treatment | |
| WO2010138095A1 (en) | Medicinal agent | |
| CN1093259A (en) | The pharmaceutical composition that is used for the treatment of senile cataract | |
| Emam et al. | Autologous PRP Usage as a Mono Therapy for the Treatment of Moderate to Severe DED | |
| CN106902344A (en) | It is a kind of to treat Chinese medicine composition of glaucoma and application thereof | |
| CN1939535A (en) | Composite collagen protein liquid | |
| Roosyidah et al. | Drug Interactions in Diabetic Ulcer Patients in an Indonesian Private Hospital | |
| JP2024072717A (en) | Ophthalmic Composition | |
| CN111588736A (en) | Artificial tear and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |